AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 191 min read$TAK

Takeda (NYSE: TAK) officer plans sale of 19,651 shares

Takeda Pharmaceutical (TAK) officer Andrew Stewart Plump plans to sell 19,651 shares, valued at $363,348.49, on or around August 19, 2026, according to a Rule 144 filing. The shares were acquired in 2020 as RSUs and PSUs.

Original reporting
stocktitan.net
Published Aug 19, 2026, 7:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The disclosed sale is routine and modest; investors should monitor for any larger insider activity.

02

Market read

Limited relevance; a small insider sale unlikely to affect Takeda's stock price.

03

What to watch

Potential upcoming regulatory or product news not disclosed could be the reason for the sale.

Relevance 4/10Novelty 4/10Timing: sale scheduled for Aug 19 2026

Background

Form 144 filings are required for insiders selling restricted shares, providing transparency on potential supply.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Form 144 filing discloses officer Andrew Stewart Plump plans to sell 19,651 Takeda shares (~$363k) on Aug 19, 2026.

Expected impact

minimal downward pressure, likely negligible impact

Evidence & confidence

Sale size is small relative to market cap and float; typical routine insider transaction.

Market effects

Sector

None; Takeda operates in pharma sector with no broader sector impact from this small sale.

Regional

No regional effect; transaction is isolated to Takeda.

Global

Insignificant on global markets.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about upcoming developments.

Key entities

  • Officer
    Andrew Stewart Plump

    Takeda officer planning the share sale.

Read at source← All news

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min